Fischer Lab

Translational research on retinal disorders

Research Projects (current)

Phase I/II clinical gene therapy trial for CNGA3 based achromatopsia

Partner: RD-CURE Consortium
Length / Duration / Start: Since 10/2012
Funding Insititution: Tistou und Charlotte Kerstan Stiftung
Results: Ongoing

Phase II clinical gene therapy trial for choroideremia

Partner: STZeyetrial, Nuffield Laboratory of Ophthalmology, NightStaRx Ltd.
Length / Duration / Start: Since 10/2014
Funding Insititution: Tistou und Charlotte Kerstan Stiftung
Results: Ongoing

Gene therapy for RPGR based retinitis pigmentosa

Partner: Nuffield Laboratory of Ophthalmology
Length / Duration / Start: Since 10/2012
Funding Insititution: UK Medical Research Council
Results: Ongoing, patent application submitted

Immunology of AAV based retinal gene therapy

Partner: Reinhild Klein, Laboratory for Immunopathology, Eberhard Karls University Tübingen
Length / Duration / Start: Since 10/2015
Funding Insititution: Tistou und Charlotte Kerstan Stiftung
Results: Ongoing

In vitro assays for gene therapy development

Partner: Stefan Liebau, Institute of Neuroanatomy, Eberhard Karls University Tübingen
Length / Duration / Start: Since 10/2015
Funding Insititution: IZKF Promotionsstipendium, Stiftung der Deutschen Wirtschaft
Results: Ongoing

Clinical disease progression in XLRP3 patients

Partner: Robert MacLaren, Nuffield Laboratory of Ophthalmology, University of Oxford; Camiel Boon, Leiden University Medical Center;
Length / Duration / Start: Since 10/2015
Funding Insititution: Studienstiftung des Deutschen Volkes
Results: Ongoing

Natural history of disease in choroideremia

Partner: STZeyetrial, NighStaRx Ltd.
Length / Duration / Start: Since 04/2014
Funding Insititution: ProRetina (travel grant), NighStaRx Ltd.
Results: Ongoing

Use of adaptive optics in patients with retinal disorders

Partner: Eberhart Zrenner
Length / Duration / Start: Since 05/2015
Funding Insititution: -
Results: Ongoing

Functional MRI in patients with retinal disorders

Partner: Georgios A. Keliris, Max Planck Institute for Biological Cybernetics; Thomas Ethofer, Werner Reichardt Centre for Integrative Neuroscience, Tübingen;
Length / Duration / Start: Since 05/2015
Funding Insititution: Tistou und Charlotte Kerstan Stiftung
Results: Ongoing

Overcoming innate immunity towards genetic therapies in the eye

Partner: SPP 2127 „Gene and Cell Based Therapies to Counteract Neuroretinal Degeneration“
Length / Duration / Start: 01/2019
Funding Insititution: DFG
Results: Ongoing